Last €22.29 EUR
Change Today -0.457 / -2.01%
Volume 250.0
NPM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:34 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

nps pharmaceuticals inc (NPM) Snapshot

Open
€21.06
Previous Close
€22.74
Day High
€22.29
Day Low
€21.06
52 Week High
02/26/14 - €28.57
52 Week Low
12/12/13 - €16.00
Market Cap
2.4B
Average Volume 10 Days
169.5
EPS TTM
--
Shares Outstanding
106.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NPS PHARMACEUTICALS INC (NPM)

nps pharmaceuticals inc (NPM) Related Businessweek News

View More BusinessWeek News

nps pharmaceuticals inc (NPM) Details

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

207 Employees
Last Reported Date: 02/18/14
Founded in 1986

nps pharmaceuticals inc (NPM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $413.7K
Senior Vice President and President of NPS Ph...
Total Annual Compensation: $395.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $407.9K
Vice President of Corporate Development & Str...
Total Annual Compensation: $223.1K
Compensation as of Fiscal Year 2013.

nps pharmaceuticals inc (NPM) Key Developments

NPS Pharmaceuticals, Inc. Reports the U.S. Food and Drug Administration Extends Prescription Drug User Fee Act (PDUFA)

NPS Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration (FDA) has extended the company's Prescription Drug User Fee Act (PDUFA) action date for its Natpara Biologics License Application (BLA) by three months from October 24, 2014 to January 24, 2015. The FDA extended the action date to provide time for a full review of a major amendment; such extensions are provided for by regulation. In addition, the FDA requested that NPS Pharma submit a Risk Evaluation and Mitigation Strategy (REMS) for Natpara and the company is working to finalize the REMS in advance of the revised PDUFA action date. To date, the FDA has not requested that additional clinical studies be completed prior to the approval of Natpara; however, the company expects a post-approval study commitment. Natpara is a bioengineered replacement therapy for endogenous parathyroid hormone (PTH) that NPS Pharma has developed for the treatment of Hypoparathyroidism, a rare endocrine disorder characterized by insufficient levels of PTH. Hypoparathyroidism is a rare endocrine disorder affecting only approximately 50,000 people in the U.S. in which the parathyroid glands fail to produce sufficient amounts of PTH or where the hormone lacks biologic activity. PTH plays a central role in a variety of critical physiological functions in the body. Insufficient levels of PTH lead to many physiological abnormalities, including low levels of calcium and high levels of phosphate in the blood, and an inability to convert native vitamin D into its active state, which helps the body properly absorb oral calcium.

Shire Is In Merger Talks With NPS

Shire plc (LSE:SHP) is considering another round of talks about a possible merger with NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP) after proposed merger of AbbVie Inc. (NYSE:ABBV) is cancelled. NPS Pharmaceuticals and Cubist Pharmaceuticals (CBST) are the two most likely merger partners for Shire plc, according to reports. Another would be merger partner is Allergan Inc. (NYSE:AGN), with the Paulson & Co. hedge fund voicing support for a deal, according to the Wall Street Journal. Allergan Inc. (NYSE:AGN) is also being pursued by Valeant Pharmaceuticals International, Inc. (TSX:VRX), but has so far rejected its entreaties. NPSP were up about 8.5% at $28.38, SHP about 3.2% at $184.93. CBST shares were up about 1.8% at $67.13.

Shire Reportedly Reopens Merger Talks with NPS And Cubist

Shire plc (LSE:SHP) is considering its acquisition options in the US following the breakdown of its £32 billion takeover by AbbVie Inc. (NYSE:ABBV). Shire reopened discussions with various takeover targets, including NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP) and Cubist Pharmaceuticals Inc. (NasdaqGS:CBST), it was reported over the weekend.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPM:GR €22.29 EUR -0.457

NPM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPM.
View Industry Companies
 

Industry Analysis

NPM

Industry Average

Valuation NPM Industry Range
Price/Earnings 100.0x
Price/Sales 16.0x
Price/Book 24.0x
Price/Cash Flow 1,477.7x
TEV/Sales 14.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS PHARMACEUTICALS INC, please visit www.npsp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.